Valeria Mateeva

Background: Generalized pustular psoriasis (GPP) is a rare, inflammatory skin disease characterized by widespread eruption of sterile pustules with or without systemic symptoms.Objectives: This study aimed to describe the demographics of patients with GPP in Central and Eastern Europe (CEE), present the clinical characteristics of individual GPP flares and explore the current treatment landscape.Methods: Patient demographics were collected at the times of last observation and previous treatment. Characteristics of a patient's last (most recent) and most severe (from all documented episodes) flare were provided at clinician's discretion.Results: Fifty‐eight patients were recruited from 12 centres in nine CEE countries; median (range) age was 61 (16–92) years and 60.3% (35 out of 58) were female. The most common comorbidities were hypertension (43.1% [25 out of 58]) and hyperlipidaemia (32.8% [19 out of 58]). Thirty‐four patients (58.6%) presented with concomitant plaque psoriasis before or during the course of GPP. Data from two separate flares were recorded in 26 individuals; in 32 patients, the most recent flare was reported as the most severe. Over 90% of patients with a flare episode classified as most severe by clinicians were hospitalized, with >75% of these individuals having a Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) total score of 3 or 4. Systemic symptoms were more common in patients with a GPPGA score of 3 or 4 but were also manifest in individuals with a GPPGA score ≤2. A significant correlation was observed between a combined systemic disease score of clinical and laboratory features and both GPPGA total score (r = 0.385, p < 0.001) and GPPGA pustulation subscore (r = 0.305, p < 0.05).Conclusions: Considerable heterogeneity in the presentation of GPP flares was observed, both between patients and within‐patient. All GPP flares were associated with a significant clinical burden, highlighting the unmet need for accurate and early diagnosis.

Programmed cell death 1 (PD-1) inhibitors used as target anti-cancer immunotherapy have been largely reported for their cutaneous immune-related | POSTER

This study was conducted to determine the characteristics of GPP flares and current treatment landscape among patients with GPP in the CEE region | POSTER

Venous leg ulcers (VLUs) are chronic difficult-to-treat wounds which affect around 1-2% of the world population. Conventional methods for treatment such as mechanical debridement, occlusive dressings and local antibiotics in case of infection, often lack effectiveness. Autologous platelet-rich plasma (PRP) is an alternative method in the treatment of chronic wounds. PRP contains inflammatory mediators, growth factors, and cytokines that modulate the wound microenvironment to create a better chance for healing. The aim of this prospective clinical study was to evaluate the efficacy of intralesional injection of PRP in the management of VLUs. This study included 23 patients with VLUs. For each patient, two ulcers located in the same anatomical zone and at the same clinical stage were selected. One was treated with a single application of autologous PRP. The other ulcer was used as a control and was treated by conventional methods. The size of the ulcers was assessed at baseline (visit 0), 15 days (visit 1) and 30 days after the procedure (visit 2). Results showed a significant reduction of the size of the ulcer both in the group treated with PRP (mean surface 1368.2 mm(2) at visit 0 and 596.3 mm(2) at visit 2) and in the control group (mean surface 880.3 mm(2) at visit 0 and 582.8 mm(2) at visit 2). Statistical analysis showed a significant change in the size of the ulcer between visit 0 and visit 2 in both groups (p < 0.0001). The application of PRP in difficultto-treat venous leg ulcers may be a promising new method for therapy of this condition. The results of this study correlate with the data from the majority of previous studies and confirm the effectiveness of PRP. Nevertheless further research in the area is needed to evaluate the therapeutic significance of the method and eventually show its superiority to conventional treatments in larger cohorts.

Background: Mycosis fungoides (MF) is the most common type of primary cutaneous peripheral T-cell lymphoma. The diagnosis of early-stage MF is challenging due to its clinical and histological resemblance to a number of benign inflammatory dermatoses. Often an immunohistochemical phenotyping is required for the diagnosis. \ud Purpose: To assess the diagnostic value of a panel of seven lymphocytic immunohistochemical markers (CD3; CD20; CD4; CD8; CD45RO; CD30; Bcl2) in the early diagnosis of MF. \ud Material/Methods: Biopsies from 30 patients with confirmed early-stage MF were stained with lymphocytic markers: CD3; CD20; CD4; CD8; CD45RO; CD30; Bcl2. The epidermal and dermal expression in this group was compared with a control group of 30 cases of benign inflammatory dermatoses, which clinically resemble MF. \ud Results: A statistically significant difference was found in the expression of CD3, CD4, CD8, CD45RO and Bcl2 in the epidermis between the two groups and the expression of CD3, CD4, CD8, CD45RO and CD30 in the dermal infiltrate. There was no statistically significant difference in the expression of CD20 and Bcl2 in the dermal infiltrate between the two groups.\ud Conclusions: There is no single marker that has enough sensitivity and specificity to be used independently for the diagnosis of MF. High epidermal expression of CD3, CD4, and CD45RO by infiltrating lymphocytes is diagnostic for MF. The most sensitive marker for MF is the CD4/CD8 ratio in the dermal infltrate; it takes into account the statistically different expression of CD4 and CD8 in both groups